SKIN Excellence

[Registration] -  🌍 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐒𝐤𝐢𝐧 𝐒𝐮𝐦𝐦𝐢𝐭 𝟐𝟎𝟐𝟓! Join us for the 𝐟𝐢𝐫𝐬𝐭 𝐞𝐝𝐢𝐭𝐢𝐨𝐧 of the 𝐒𝐤𝐢𝐧 𝐒𝐮𝐦𝐦𝐢𝐭, an international conference on dermatology innovation, by Eurobiomed, taking place on 𝐀𝐩𝐫𝐢𝐥 𝟐𝟒-𝟐𝟓, 𝟐𝟎𝟐𝟓 at 𝐀𝐧𝐭𝐢𝐛𝐞𝐬 𝐜𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝐂𝐞𝐧𝐭𝐞𝐫. This unique event will bring together international experts, researchers, and healthcare professionals to explore the latest breakthroughs and technologies in skin health. 🔬 𝐖𝐡𝐚𝐭 𝐭𝐨 𝐞𝐱𝐩𝐞𝐜𝐭: •   Keynote presentations from thought leaders •   Interactive workshops on dermatology innovations •   Networking opportunities with key players in the field 🎉 𝐒𝐩𝐞𝐜𝐢𝐚𝐥 𝐨𝐟𝐟𝐞𝐫:  Exclusively for Eurobiomed members - enjoy a 𝟏𝟎% 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭 on your registration! 🔗𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐡𝐞𝐫𝐞: https://lnkd.in/eqT4ewBe Be part of the future of skin health! 💡 Contact : Cloëlle FILAIN #SkinSummit2025 #Innovation #Dermatology #Eurobiomed #Conference #SkinHealth

[New article in The Lancet] 📰Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. 📣Professor Passeron, first author of this article, will be speaking at the Rencontre Thématique In Dermatology on November 7&8 in Sophia Antipolis (Valbonne), and at the Skin Summit on April 24&25, 2025 in Juan-les-Pins. Unique opportunities to explore the latest advances and innovations in dermatology! 📝Register now for The Rencontre Thématique in Dermatology : https://lnkd.in/eCGT385h 📰Article : https://lnkd.in/eiXedv7U

[Reminder] - 📢 𝐎𝐧𝐥𝐲 𝟐 𝐰𝐞𝐞𝐤𝐬 𝐥𝐞𝐟𝐭 "𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘵𝘰 𝘵𝘩𝘦 𝘤𝘰𝘯𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘪𝘯 𝘥𝘦𝘳𝘮𝘢𝘵𝘰𝘭𝘰𝘨𝘺 𝘵𝘰 𝘦𝘹𝘱𝘭𝘰𝘳𝘦 𝘤𝘶𝘵𝘵𝘪𝘯𝘨-𝘦𝘥𝘨𝘦 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘥𝘦𝘳𝘮𝘢𝘵𝘰𝘭𝘰𝘨𝘺!" 📆 On November 7 (evening) and 8, come and discover the latest innovations to meet dermatological challenges, both in terms of diagnosis and future treatments. ✏️ More information and registration for networking, conferences and B2B, on the following link : https://lnkd.in/eCGT385h If needed, contact us :  Eloïse Gouarin eloise.gouarin@eurobiomed.org Cloëlle FILAIN cloelle.filain@eurobiomed.org

Come and meet some of the members of our community, working for the greater good in skin health ! More info and registration : https://lnkd.in/eCGT385h If needed, contact Alexandra Beltoise

[𝑁𝑒𝑤 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑖𝑛 𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑂𝑛𝑐𝑜𝑙𝑜𝑔𝑦] 📰 "𝐏𝐏𝐑𝐗𝟏 𝐬𝐢𝐥𝐞𝐧𝐜𝐢𝐧𝐠 𝐢𝐬 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐝 𝐟𝐨𝐫 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐨𝐮𝐭𝐠𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐚𝐧𝐝 𝐢𝐬 𝐚𝐧 𝐢𝐧𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐨𝐟 𝐫𝐞𝐝𝐮𝐜𝐞𝐝 𝐬𝐮𝐫𝐯𝐢𝐯𝐚𝐥 𝐢𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬" Malignant melanoma is one of the most aggressive forms of skin cancer, whose progression relies on the plasticity of tumor cells, making them able of adapting to microenvironments in response to extracellular signals. Most of these changes are carried out by a non-genetic process known as epithelial-mesenchymal transition (EMT). We know that aired-related homebox 1 (PRRX1) is a transcription factor that regulates the EMT process through different signaling pathways in different types of cancer cells, and confers migratory and invasive properties to mesenchymal cells that caracterize them. Through this research, the investigators revealed low expression of PRRX1 in nevi, but increased levels in primary human melanomas and cell lines carrying a virus (BRAFV600E). These results support the idea that loss of PRRX1 in melanoma cells promotes a phenotypic change that counteracts the EMT phenotypic, by altering the expression of other transcription factors, causing dysregulation of certain signaling pathways and inhibiting the invasive and migratory properties of melanoma cells.

[𝑇ℎ𝑒 𝐸𝑢𝑟𝑜𝑝𝑒𝑎𝑛 𝐶𝑜𝑛𝑔𝑟𝑒𝑠𝑠 𝑜𝑛 𝐷𝑒𝑟𝑚𝑎𝑡𝑜-𝑂𝑛𝑐𝑜𝑙𝑜𝑔𝑦] 📅 When ? October 31st and November 1, 2024 📍 Where ? Vienna, Austria We inform and invite you to participate at the European Dermato-Oncology Congress which will take place from October 31rt to November 1rt, 2024 in the beautiful and historic city of Vienna. A large audience of oncologists, clinical scientists and other experts will gather and exchange on the latest developments and discoveries in the diagnosis and management of different types of skin cancer. An opportunity to develop your knowledge, find new collaborators and partners, and gain exposure to international perspectives. Join Drmato-Oncology2024, the future congress focusing on a number of key areas and encouraging you to take and active part in a rewarding, collective event.

[𝑁𝑒𝑤 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑖𝑛 𝑆𝑘𝑖𝑛 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑎𝑛𝑑 𝑇𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑦] 📰 "𝐦𝟔𝐀-𝐚𝐧𝐝 𝐦𝟓𝐂-𝐦𝐨𝐝𝐢𝐟𝐢𝐞𝐝 𝐈𝐧𝐜𝐑𝐍𝐀𝐬 𝐨𝐫𝐜𝐡𝐞𝐬𝐭𝐫𝐚𝐭𝐞 𝐭𝐡𝐞 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐢𝐬 𝐢𝐧 𝐜𝐮𝐭𝐚𝐧𝐞𝐨𝐮𝐬 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐚𝐧𝐝 𝐦𝟔𝐀-𝐦𝐨𝐝𝐢𝐟𝐢𝐞𝐝 𝐋𝐈𝐍𝐂𝟎𝟎𝟖𝟗𝟑 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐞𝐬 𝐜𝐮𝐭𝐚𝐧𝐞𝐨𝐮𝐬 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐜𝐞𝐥𝐥 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐬𝐢𝐬" Cutaneous melanoma (SKCM) is a tumor with a poor prognosis. Although mortality rates for melanoma have declined, it remains the malignant tumor arising from melanocytes. To date, reports associated with cutaneous melanoma are rare, but recent clinical trials have demonstrated the importance of immune checkpoint inhibitors and BRAF/MEF inhibitors in the overall survival of patients with avanced melanoma. Numerous studies have shown that IncRNA can affect the malignant behaviour of skin tumours, but also of many inflammatory skin diseases. This study highlights two key points : - The identification of 27 IncRNAs linked to m6A and m5C that would be significantly associated with survival. -The discovery of LINC00893, potentials regulated by the m6A modification and could serve as a tumor suppressor in melanoma. This raise the question of the importance of processes such as RNA splicing, stability or translation that could be regulated after m6A or m5C.

[𝑅𝑜𝑚𝑒, 𝑋𝐼𝑉 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝐶𝑜𝑛𝑔𝑟𝑒𝑠𝑠 𝑜𝑓 𝐷𝑒𝑟𝑚𝑎𝑡𝑜𝑙𝑜𝑔𝑦] 📅 When ? June 18th-21st, 2025 📍 Where? Triumph Italy, Rome The 14th edition of the International Congress of Dermatology (ICD) will be held in Rome from June 18 to 21, 2025. Held every 4 years, this international congress will be an opportunity to meet and exchange experiences with dermatology professionals from all over the world who share the same passion for scientific and clinical knowledge. An exceptional three-day scientific program covering topics such as medical dermatology, new therapies, infectious diseases and much more ! Join this historic city to celebrate the spirit of dermatology with speacial rates reserved for congress participants you'll find upcoming details on their website : https://lnkd.in/eq8752gd

[𝑁𝑒𝑤 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑖𝑛 𝑆𝑘𝑖𝑛 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑎𝑛𝑑 𝑇𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑦] 📰 "𝐆𝐞𝐧𝐞𝐭𝐢𝐜 𝐜𝐚𝐮𝐬𝐚𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐭𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲𝐢𝐧𝐠 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐢𝐨𝐧𝐬𝐡𝐢𝐩 𝐨𝐟 𝐛𝐥𝐨𝐨𝐝 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐭𝐞𝐬 𝐚𝐧𝐝 𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬" Psoriasis affects millions of people worldwide, and although much research is being carried out on the subject, its pathological mechanism remains complex, and little is known about the underlying metabolic mechanisms. Associated with significant disability, psoriasis is a chronic inflammatory disease characterized by erythematous and squamous plaques over a wide area on the skin. In this study, the investigators assessed the potential association between human blood metabolites and psoriasis through different genetic analyses. On the basis of the metabolites selected, the metabolic pathway analysis suggested sever metabolic pathways for metabolites in psoriasis. Unsaturated fatty acids would therefore be considered protective factors against psoriasis. Although there are several limiting factors to this study, lipids therefore play an essential role in the pathogenesis of psoriasis, with a unique effect on pathogenesis in different sexes.

[𝑁𝑒𝑤 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑖𝑛 𝐽𝑜𝑢𝑟𝑛𝑎𝑙 𝑜𝑓 𝐶𝑜𝑠𝑚𝑒𝑡𝑖𝑐 𝐷𝑒𝑟𝑚𝑎𝑡𝑜𝑙𝑜𝑔𝑦] 📰 "𝐇𝐨𝐦𝐨𝐜𝐲𝐬𝐭𝐞𝐢𝐧𝐞 𝐢𝐧 𝐚𝐧𝐝𝐫𝐨𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐚𝐥𝐨𝐩𝐞𝐜𝐢𝐚 : 𝐀 𝐜𝐚𝐬𝐞 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐬𝐭𝐮𝐝𝐲 𝐚𝐧𝐝 𝐨𝐛𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐞𝐱𝐩𝐞𝐫𝐢𝐦𝐞𝐧𝐭𝐬 𝐨𝐧 𝐦𝐢𝐜𝐞" Androgenetic alopecia (AGA) is a widespread, non-healing type of hair disorder caused by abnormal hair follicle sensitivity and excessive dihydrotestosterone (DHT) synthesis. In this study, researchers looked at the relationship between homocysteine (HCY) and androgenetic alopecia (AGA) using observation experiments on batches of mice (healthy or with AGA). Several experiments have been carried out, leading to preliminary results. There is a potential relationship between HCY and AGA, leading to the precocious appearance of AGA. In addition, HCY could act at a certain stage of hair promotion or HF development and play a role in the onset of alopecia. Although the results are an encouraging firt step, they remain preliminary and will require further in vitro experiments to explain the specific mechanism by which HCY is involved in the pathogenesis of AGA